Single Arm, Open Label Trial With Iptacopan Treatment for 24 Weeks, in Patients on Stable Regimen of Anti-C5 Who Switch to Iptacopan.
NCT05630001
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
52
Enrollment
INDUSTRY
Sponsor class
Conditions
Paroxysmal Nocturnal Hemoglobinuria
Interventions
DRUG:
Iptacopan
Sponsor
Novartis Pharmaceuticals